Your browser doesn't support javascript.
loading
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola, Nestor F; Chaudhary, Uzair B; O'Brien, Paul; Garrett-Mayer, Elizabeth; Camp, E Ramsay; Thomas, Melanie B; Cole, David J; Montero, Alberto J; Hoffman, Brenda J; Romagnuolo, Joseph; Orwat, Kelly P; Marshall, David T.
Afiliação
  • Esnaola NF; Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Chaudhary UB; Division of Hematology and Oncology, Department of Internal Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • O'Brien P; Division of Hematology and Oncology, Department of Internal Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Garrett-Mayer E; Division of Biostatistics and Epidemiology, Department of Internal Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Camp ER; Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Thomas MB; Division of Hematology and Oncology, Department of Internal Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Cole DJ; Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Montero AJ; Division of Hematology and Oncology, Department of Internal Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Hoffman BJ; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Romagnuolo J; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Orwat KP; Department of Radiation Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Marshall DT; Department of Radiation Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina. Electronic address: marshadt@musc.edu.
Int J Radiat Oncol Biol Phys ; 88(4): 837-44, 2014 Mar 15.
Article em En | MEDLINE | ID: mdl-24606850
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Radioterapia de Intensidade Modulada / Quimiorradioterapia / Quimioterapia de Indução Tipo de estudo: Guideline Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Radiat Oncol Biol Phys Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Radioterapia de Intensidade Modulada / Quimiorradioterapia / Quimioterapia de Indução Tipo de estudo: Guideline Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Radiat Oncol Biol Phys Ano de publicação: 2014 Tipo de documento: Article